开发一种新的UPLC方法,用于在多组分制剂中共同预测四种活性化合物
Özgür Üstündağ1, Asiye Üçer2, Erdal Dinç1
1Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, 06560 Yenimahalle, Ankara, Turkey.
概括
一种新的超高性能液态色谱法 (UPLC-PDA) 能够准确量化药物配方中的酸 (AA), (PAR),咖啡因 (CAF) 和胺酸 (CPA) 的含量. 这种方法为这四种活性药物成分提供了快速简单的分析.
科学领域:
- 分析化学 分析化学
- 药品分析 药品分析
背景情况:
- 药物组合药物中多种活性药物成分 (API) 的准确量化对于质量控制至关重要.
- 对于复杂的药物配方,现有的分析方法可能缺乏效率或简单性.
研究的目的:
- 开发和验证一种新型的超高性能液体色谱方法,用于四个API的同时定量分析.
- 建立一个快速而简单的分析技术,以商用剂型的四元混合物.
主要方法:
- 开发 UPLC-PDA 方法,使用水域水分 UPLC BEH C18 列.
- 优化由水,乙和酸 (H3PO4) 组成的移动相.
- 通过对合成混合物的分析,日间/日内精度和商业样本进行方法验证.
主要成果:
- 成功的染色分离了亚酸 (AA), (PAR),咖啡因 (CAF) 和胺酸 (CPA).
- UPLC-PDA方法显示出高准确度和精度,在验证过程中提供了令人满意的结果.
- 实现了较短的运行时间和简化样本准备,以共同确定四种药物.
结论:
- 开发的UPLC-PDA方法适用于精确和高效的定量分析指定的四元混合物.
- 这种方法为含有这四种API的药品的质量控制提供了有价值的工具.
- 该方法在药物组合中共同确定多种活性成分方面取得了重大进展.
更多相关视频
11:25Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
Published on: July 11, 2014
33.6K
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
9.6K
相关概念视频
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
413
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
413
01:20Drug Product Performance: In Vitro–In Vivo Correlation
392
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
392